FSHD - Med Pharma News

Graphic: Soufflé Therapeutics $135 million funding, RNA delivery arrows pointing from the liver toward the heart and muscle with a $135M Series B label

Soufflé Therapeutics $135 Million Funding: Powerful Boost for RNA Drugs

Megan Wood4 hours ago4 hours ago011 mins

Soufflé Therapeutics $135 million funding backs RNA drugs for FSHD and heart failure. The treatments are experimental; no new human data were reported.